Skip to content
OpenCapital
Get started

Organon OGN Fosamax — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Biogen logo
BIIBFumarate — Total Revenue
$288.5M-16.4%
Biogen logo
BIIBFAMPYRA — Total Revenue
$0-100%
Amgen logo
AMGNProlia — Total revenues
$727M-33.8%
Gilead Sciences logo
GILDProduct sales — Total revenues
$6.95B+5.0%
Bristol-Myers Squibb logo
BMYCobenfy — Total Revenues
$56M+107%
Biogen logo
BIIBTecfidera — Revenue
$2.48B+1.9%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's fosamax — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's fosamax — revenue?
Organon (OGN) reported fosamax — revenue of $29M in Q1 2026.
How has Organon's fosamax — revenue changed year-over-year?
Organon's fosamax — revenue decreased by 12.1% year-over-year, from $33M to $29M.
What is the long-term trend for Organon's fosamax — revenue?
Over 4 years (2021 to 2025), Organon's fosamax — revenue has grown at a -5.1% compound annual growth rate (CAGR), from $176M to $143M.
What does fosamax — revenue mean?
Represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeutic brand within the company's portfolio. This metric tracks the commercial performance and market demand for the product over a defined fiscal period. It serves as a key indicator of the product's contribution to the company's overall top-line growth and market relevance.